Thalidomide remains an active drug on the pharmaceutical market
Thalidomide remains an active drug on the pharmaceutical market, having successfully transitioned from its historical withdrawal to a widely studied and utilized repurposed agent for multiple myeloma, immunological conditions, and inflammatory disorders.
The retrieved literature consistently demonstrates that while thalidomide was historically withdrawn due to teratogenicity scandals, it has since re-entered modern clinical practice as an actively prescribed and researched repurposed drug for multiple myeloma, digestive diseases, and various inflammatory or refractory conditions.
Al-Odat OS, Nelson E, Budak-Alpdogan T, Jonnalagadda SC, Desai D, Pandey MK. Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients.. 2024. https://doi.org/10.3390/cancers16132381
Thalidomide is highlighted as a successful repurposed drug for treating conditions like multiple myeloma.
See more details
Xi Z, Jie W, Long Z, Shasha S. A review of thalidomide and digestive system related diseases.. 2025. https://doi.org/10.3389/fonc.2025.1543757
The drug remains in clinical use and is actively studied for digestive disorders and other conditions despite past controversies.
Ciccarelli S, Perrone C, Cavalera MA, Giuliano A. Drug Repurposing in Veterinary Oncology: Myth or Reality?. 2025. https://doi.org/10.3390/vetsci12111067
Thalidomide is classified as an active immunomodulatory therapeutic agent in veterinary oncology and human medicine.
Yan X, Guo Z, Lyu C, Tang R, Li R, Wang H, Song K, Chen W, He K, Wu D. Renaissance of Phoenix Drug Thalidomide-New Insights into Practical Clinical Application and Optimization Strategies for Managing Adverse Effects in Digestive Diseases.. 2025. https://doi.org/10.3390/ph18111689
Thalidomide has re-emerged as a repurposed agent for a broad spectrum of diseases, acting as a modern phoenix drug.
Kan SY, Sung YK, Hsu CL, Chiu KC. Successful Remission of Refractory Oral Ulcers Treated with Low-Dose Thalidomide and Colchicine: A Case Report.. 2026. https://doi.org/10.3390/reports9010036
Low-dose thalidomide is successfully prescribed in clinical case reports for the treatment of refractory oral ulcers.
Zhang Y, Zheng P, Hu B, Chen L. Tofacitinib combined with fire needle therapy for refractory cutaneous Rosai-Dorfman disease: a first case report and literature review.. 2026. https://doi.org/10.3389/fmed.2026.1771685
Clinical histories document patients receiving thalidomide as part of established pharmacological interventions for immunological conditions.
Sun QG, Zang D, Xin Y, Cui J, Han X, Chen J. Multi-omics Analysis Reveals the Correlation of Gut Microbiota and Metabolites With Thalidomide Treatment for Chemotherapy-Induced Nausea and Vomiting in Small Cell Lung Cancer.. 2026. https://doi.org/10.1002/biot.70228
Thalidomide is actively utilized in clinical settings to manage chemotherapy-induced nausea and vomiting in cancer patients.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt